RBC Capital Lowers Its Price Target on Viridian Therapeutics, Inc. (VRDN) to $42 and Maintains an Outperform Rating

Viridian Therapeutics, Inc. (NASDAQ:VRDN) is among the 10 Fastest Growing NASDAQ Stocks to Buy.

On February 27, 2026, RBC Capital lowered its terms people connected Viridian Therapeutics, Inc. (NASDAQ:VRDN) to $42 from $45 and maintained an Outperform rating. The expert noted the institution reported Q4 EPS and disclosed that veli’ PDUFA is scheduled for June 30, with preparations underway for a imaginable commercialized motorboat successful thyroid oculus illness successful mid-2026 if approved. RBC said it continues to favour the company’s positioning successful 2026 arsenic it could modulation to the commercialized signifier and determination person to profitability.

On February 26, 2026, Jefferies raised its terms people to $45 from $44 and kept a Buy rating. The steadfast said each cardinal events stay connected way and that capitalist absorption is connected the Phase 3 topline readout of subcutaneous elegrobart successful REVEAL-1 successful Q1, REVEAL-2 successful Q2, and the PDUFA determination owed June 30 for intravenous veligrotug nether precedence review.

That aforesaid day, Viridian Therapeutics reported Q4 EPS of ($1.08), compared to the ($1.00) statement estimate. Q4 gross was $132,000 versus the statement of $15.75M. President and Chief Executive Officer Steve Mahoney said the institution enters 2026 with continued execution momentum, highlighting the veligrotug BLA filing nether Priority Review and a June 30, 2026, PDUFA people date. He added that the MAA submission to the EMA supports the planetary accidental for veligrotug and that REVEAL-1 topline information for elegrobart is expected adjacent month, with the extremity of establishing veligrotug and elegrobart arsenic foundational therapies for TED portion advancing the broader pipeline.

Viridian Therapeutics, Inc. (NASDAQ:VRDN) discovers, develops, and commercializes treatments for superior and uncommon diseases, including IGF-1R therapies for thyroid oculus disease.

While we admit the imaginable of VRDN arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you’re looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 12 Best Tech Stocks that Beat Earnings Estimates and 40 Most Popular Stocks Among Hedge Funds Heading Into 2026

Disclosure: None. Follow Insider Monkey connected Google News.